JP2022524218A5 - - Google Patents

Info

Publication number
JP2022524218A5
JP2022524218A5 JP2021559064A JP2021559064A JP2022524218A5 JP 2022524218 A5 JP2022524218 A5 JP 2022524218A5 JP 2021559064 A JP2021559064 A JP 2021559064A JP 2021559064 A JP2021559064 A JP 2021559064A JP 2022524218 A5 JP2022524218 A5 JP 2022524218A5
Authority
JP
Japan
Prior art keywords
aso
seq
angptl2
lna
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021559064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524218A (ja
JP7725370B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/026379 external-priority patent/WO2020206115A2/en
Publication of JP2022524218A publication Critical patent/JP2022524218A/ja
Publication of JP2022524218A5 publication Critical patent/JP2022524218A5/ja
Priority to JP2025131153A priority Critical patent/JP2026002846A/ja
Application granted granted Critical
Publication of JP7725370B2 publication Critical patent/JP7725370B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021559064A 2019-04-03 2020-04-02 Angptl2アンチセンスオリゴヌクレオチドおよびその使用 Active JP7725370B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025131153A JP2026002846A (ja) 2019-04-03 2025-08-06 Angptl2アンチセンスオリゴヌクレオチドおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962828864P 2019-04-03 2019-04-03
US62/828,864 2019-04-03
PCT/US2020/026379 WO2020206115A2 (en) 2019-04-03 2020-04-02 Angptl2 antisense oligonucleotides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025131153A Division JP2026002846A (ja) 2019-04-03 2025-08-06 Angptl2アンチセンスオリゴヌクレオチドおよびその使用

Publications (3)

Publication Number Publication Date
JP2022524218A JP2022524218A (ja) 2022-04-28
JP2022524218A5 true JP2022524218A5 (cg-RX-API-DMAC7.html) 2023-04-10
JP7725370B2 JP7725370B2 (ja) 2025-08-19

Family

ID=70465458

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559064A Active JP7725370B2 (ja) 2019-04-03 2020-04-02 Angptl2アンチセンスオリゴヌクレオチドおよびその使用
JP2025131153A Pending JP2026002846A (ja) 2019-04-03 2025-08-06 Angptl2アンチセンスオリゴヌクレオチドおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025131153A Pending JP2026002846A (ja) 2019-04-03 2025-08-06 Angptl2アンチセンスオリゴヌクレオチドおよびその使用

Country Status (13)

Country Link
US (1) US20220213484A1 (cg-RX-API-DMAC7.html)
EP (1) EP3947680A2 (cg-RX-API-DMAC7.html)
JP (2) JP7725370B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210149107A (cg-RX-API-DMAC7.html)
CN (1) CN113906139A (cg-RX-API-DMAC7.html)
AU (1) AU2020252374A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019182A2 (cg-RX-API-DMAC7.html)
CA (1) CA3135794A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192733A1 (cg-RX-API-DMAC7.html)
IL (1) IL286826A (cg-RX-API-DMAC7.html)
MX (1) MX2021012098A (cg-RX-API-DMAC7.html)
SG (1) SG11202110745VA (cg-RX-API-DMAC7.html)
WO (1) WO2020206115A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3131970B1 (fr) 2022-01-14 2024-02-23 Univ D’Aix Marseille Amu Dispositif pour la simulation en chirurgie abdominale

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JP2823959B2 (ja) 1991-10-24 1998-11-11 アイシス・ファーマシューティカルス・インコーポレーテッド 改良された取り込みおよびその他の性質を持つ誘導化オリゴヌクレオチド
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
EP1015469B2 (en) 1997-09-12 2015-11-18 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
JPH11341989A (ja) * 1998-03-31 1999-12-14 Sanyo Electric Co Ltd Dna断片増幅方法、dna断片増幅装置、微生物群測定方法、微生物群分析方法および汚染物質測定方法
BRPI0008131B8 (pt) 1999-02-12 2021-05-25 Daiichi Sankyo Co Ltd composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
AU4066800A (en) * 1999-04-01 2000-10-23 Genetics Institute Inc. Angiopoietin-like proteins, crisp proteins and polynucleotides encoding same
ATE356824T1 (de) 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
EP2284269B1 (en) 2002-11-18 2017-08-09 Roche Innovation Center Copenhagen A/S Antisense design
AU2004221760B2 (en) 2003-03-21 2010-03-18 Roche Innovation Center Copenhagen A/S Short interfering RNA (siRNA) analogues
US20070072209A1 (en) * 2005-07-07 2007-03-29 Ashlee Moses Methods of treatment and diagnosis of Kaposi's sarcoma (KS) and KS related diseases
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
WO2007085485A2 (en) 2006-01-27 2007-08-02 Santaris Pharma A/S Lna modified phosphorothiolated oligonucleotides
DE602007009487D1 (de) 2006-01-27 2010-11-11 Isis Pharmaceutical Inc 6-modifizierte bicyclische nukleinsäureanaloga
ES2556128T3 (es) 2006-03-23 2016-01-13 Roche Innovation Center Copenhagen A/S ARN interfiriente pequeño internamente segmentado
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
DK2170917T3 (da) 2007-05-30 2012-10-08 Isis Pharmaceuticals Inc N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
EP2963116B1 (en) * 2009-03-04 2020-11-11 CuRNA, Inc. Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
JP2011093896A (ja) * 2009-09-30 2011-05-12 Kumamoto Univ 癌治療剤
US9364495B2 (en) 2009-10-20 2016-06-14 Roche Innovation Center Copenhagen A/S Oral delivery of therapeutically effective LNA oligonucleotides
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
SI3505528T1 (sl) * 2011-04-21 2021-04-30 Glaxo Group Limited Modulacija izražanja virusa hepatitisa B (HBV)
US10023861B2 (en) 2011-08-29 2018-07-17 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
JP2015502365A (ja) * 2011-12-12 2015-01-22 オンコイミューニン,インコーポレイティド オリゴヌクレオチドのイン−ビボ送達
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
CA2889044A1 (en) 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
WO2014167529A1 (en) * 2013-04-10 2014-10-16 Institut De Cardiologie De Montreal Methods and compositions for preventing and treating atherosclerosis
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
EP3007705A4 (en) * 2013-06-12 2017-02-15 Oncoimmunin, Inc. Systemic in vivo delivery of oligonucleotides
MX367083B (es) 2013-06-27 2019-08-05 Roche Innovation Ct Copenhagen As Oligomeros antisentido y conjugados con diana en la proteina-convertasa subtilisina/kexina tipo 9(pcsk9).
WO2016081444A1 (en) * 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
CA2975525A1 (en) * 2015-02-04 2016-08-11 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
JP6978774B2 (ja) * 2015-11-06 2021-12-08 国立大学法人 熊本大学 心不全の予防又は治療のための医薬組成物
WO2018098328A1 (en) 2016-11-23 2018-05-31 Alnylam Pharmaceuticals, Inc. Modified rna agents with reduced off-target effect
JP7557469B2 (ja) * 2019-01-29 2024-09-27 アイオーニス ファーマシューティカルズ, インコーポレーテッド Appの発現を低減するための化合物及び方法

Similar Documents

Publication Publication Date Title
JP2021513861A5 (cg-RX-API-DMAC7.html)
IL276549B1 (en) CAMK2D antisense oligonucleotides and their uses
JP7798836B2 (ja) B型肝炎感染の治療用のPAPD5及びPAPD7 mRNAを低減させるための核酸分子
JP2025179845A (ja) Atxn2発現を制御するためのオリゴヌクレオチド
JP2021510511A5 (cg-RX-API-DMAC7.html)
KR20170007414A (ko) 올리고머 및 올리고머 접합체
IL275903B1 (en) Antisense oligonucleotides targeting alpha-synuclein and uses thereof
JP2000514093A (ja) Cmv感染症の治療のための組成物および方法
JP2025166835A (ja) B型肝炎ウイルス感染を処置するためのscamp3阻害剤の使用
CN114901821A (zh) Sept9抑制剂用于治疗乙型肝炎病毒感染的用途
WO2007137301A2 (en) Modulation of chrebp expression
JP2026002846A (ja) Angptl2アンチセンスオリゴヌクレオチドおよびその使用
JP2025094072A (ja) B型肝炎ウイルス感染を処置するためのcops3阻害剤の使用
EP3568481A1 (en) Antisense oligonucleotides for modulating relb expression
JP2024026274A (ja) マイクロrna関連疾患の処置のための薬学的組成物
JP2023506550A (ja) B型肝炎ウイルス感染症を処置するためのsbds阻害剤の使用
CN114829603A (zh) 用于抑制scn9a表达的增强寡核苷酸
WO2019038228A1 (en) OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
EP3568479A1 (en) Antisense oligonucleotides for modulating nfkb1 expression
WO2025090254A1 (en) Adnp syndrome antisense treatment
HK40078459A (en) Use of scamp3 inhibitors for treating hepatitis b virus infection
CN121941769A (zh) Ppp1r15b rna干扰剂
HK40078456A (en) Use of sbds inhibitors for treating hepatitis b virus infection
HK40071185A (en) Use of sept9 inhibitors for treating hepatitis b virus infection
RU2022113237A (ru) Антисмысловые олигонуклеотиды к альфа-синуклеину и их применения